CTOs on the Move

Tarsus Pharmaceuticals

www.tarsusrx.com

 
Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tarsusrx.com
  • 15440 Laguna Canyon Road Suite 160
    Irvine, CA USA 92618
  • Phone: 949.409.9820

Executives

Name Title Contact Details

Funding

Tarsus Pharmaceuticals raised $60M on 01/08/2020
Tarsus Pharmaceuticals raised $75.6M on 05/03/2022

Similar Companies

Kuros Biosciences

Pioneering solutions for targeted and controlled bone healing. Join us in our mission to eliminate non-unions and improve patient rehabilitation.

TriRx

Advance with TriRx. Your contract development & manufacturing organization focused on non-sterile & sterile products, animal health injectables & packaging.

Asian Health Services

We offer medical, dental and behavioral health care for Alameda Countys underserved Asian and Pacific Islander community.

Acatris

Acatris Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.